Physician profile
Sameer A Parikh
NPI 1841419348
$151,318.25
in general payments reported to CMS, 2019-2025
18 companies · $34K in 2025
The $34K reported for 2025 was more than what 90% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $27K · 2021: $22K · 2022: $9,885 · 2023: $6,776 · 2024: $24K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $62K · Travel and Lodging: $1,296 · Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,421.75 |
| Travel and Lodging | $1,295.91 |
| Food and Beverage | $666.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $45,997.63 | 2019-2025 | Calquence |
| Abbvie INC. | $26,312.77 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $23,210.50 | 2022-2025 | |
| Janssen Global Services, LLC | $9,485.00 | 2021-2024 | Imbruvica |
| Glaxosmithkline, LLC. | $9,415.95 | 2019-2020 | |
| Genentech, INC. | $7,340.27 | 2019-2022 | |
| Verastem, INC. | $5,760.44 | 2019 | |
| Astrazeneca Uk Limited | $5,173.74 | 2019 | |
| Genentech USA, INC. | $4,647.50 | 2020-2022 | |
| Sobi, INC | $4,235.00 | 2025 | |
| Gilead Sciences, INC. | $2,700.00 | 2022 | |
| Tg Therapeutics, INC. | $2,025.00 | 2021 | |
| Amgen INC. | $1,947.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $1,567.45 | 2019 | |
| Adaptive Biotechnologies Corporation | $1,500.00 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.